ABSTRACT

Background: Pharmacoeconomics estimates the value of pharmaceutical products and services and provides healthcare decision-makers with valuable information. Pharmacoeconomic evaluations have not been found to be influential in the Jordanian health care system. Although pharmacoeconomics as a concept is becoming more recognized in the pharmaceutical world, there are still some barriers to its implementation.

Objective: To establish the perceived barriers to the implementation of pharmacoeconomics in Jordan.

Method: A qualitative study with semi-structured interviews was conducted. Participants were chosen if they might benefit from the application of pharmacoeconomics; such as members of Pharmacy and Therapeutics Committees (PTCs) in public, private, and teaching hospitals; administrative pharmacists on drug pricing committees; those who produce pharmacoeconomic data such as academics; and administrative pharmacists in the Joint Procurement Department (JPD). The interviews were recorded and transcribed. Transcripts were analyzed using a thematic analysis approach.

Result: Three main barriers to the implementation of pharmacoeconomics were identified. These were related to the nature of the decision-making process, the lack of pharmacoeconomic data, and inadequate knowledge about pharmacoeconomics.

Conclusion: The current use and impact of pharmacoeconomic evaluations in Jordanian healthcare decision-making is restricted, in part, due to the barriers outlined by the respondents.

摘要

背景：药物经济学估算药物产品和服务的价值，并为医疗保健决策者提供有价值的信息。还没有发现药物经济学评估对约旦的医疗体系有影响。尽管药物经济学作为一个概念已在制药界得到越来越多的认可，但实施它仍然存在一些障碍。

目的：建立在约旦实施药物经济学的公认障碍。

方法：进行了半结构化访谈的定性研究。选择参加者是否可以从药物经济学的应用中受益；例如公立，私立和教学医院的药学和治疗学委员会（PTC）的成员；药品定价委员会的行政药剂师；产生药物经济学数据的人，例如学者；和联合采购部（JPD）的行政药剂师。采访记录并转录。使用主题分析方法分析成绩单。

结果：确定了实施药物经济学的三个主要障碍。这些与决策过程的性质，药物经济学数据的缺乏以及对药物经济学的知识不足有关。

结论：约旦医疗决策中药物经济学评估的当前用途和影响受到限制，部分原因是受访者提出了障碍。